Diagnostic accuracy of E-cadherin for malignanteffusions: a systematic review and meta-analysis

Abstract

BackgroundThe differential diagnosis of malignant effusion remains a clinical challenge. We aim to summarise all relevant literature studies in order to determine the overall clinical value of E-cadherin in the diagnosis of malignant effusion by meta-analysis.MethodsPubMed, the Cochrane Library Database, Medline (Ovid), Web of Science, CNKI, WANFANG and WEIPU databases are thoroughly searched up to 15 March2018. The calculated pooled sensitivity, specificity, likelihood ratio (LR), diagnostic OR(DOR) and the summary receiver operating characteristic (SROC) curvewere plotted.ResultsA total of 15 studies were included in the analysis. The sensitivity and specificity of E-cadherin in the diagnosis of malignant effusion were determined to be high, with a sensitivity of 0.83(95%CI0.79 to 0.87) and a specificity of 0.96(95%CI0.90 to 0.98). The positive LR was determined to be 21.10(95%CI 8.54 to 52.11), the negative LR was determined to be 0.17(95% CI 0.14 to 0.22) and the DOR was determined to be 121.34(95%CI 49.11 to 299.80). The SROC curve exhibited a high overall diagnostic, with the area under the curve measured to be 0.91(95% CI 0.89 to 0.93). Subgroup analysis showed the method (cell blocks or smears), sample size (≥100 or<100), geographical location (Asia, Europe or USA) and impact factor of each article (≥3 or<3) were not the sources of overall heterogeneity.ConclusionE-cadherin exhibits very good diagnostic accuracy for the diagnosis for malignant effusion; thus, it can be helpful in the process of clinical decisions.

Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein

“…Therefore, EMT is characterized by the loss of E-cadherin and acquisition of vimentin [19][20][21]. In this study, Jolkinolide B inhibited EMT progression, resulting in an increase in E-cadherin and a decrease in vimentin levels.…”

Hsa_circ_0013561 promotes progression of nasopharyngeal carcinoma by activating JAK2/STAT3 signaling pathway

“…E-cadherin is a potential marker of malignancy. 24 , 25 N-cadherin is a transmembrane adhesion molecule associated with advanced cancer progression and poor prognosis. Increased expression of N-cadherin is a marker of EMT and promotes tumor cell survival, migration, and invasion.…”